Coloplast Corp
$6.0M 19,137 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Envista Holdings Corporation
Envista Holdings Corporation reported $5,991,891.20 across General Payments, Research, and Ownership to 14,689 physicians and teaching hospitals across 14,709 transactions.
- $6.0M
- All-tracks total
- 14,709
- Transactions
- 14,689
- Recipients
- #244
- of 1,925 companies
Envista Holdings Corporation reported $5,991,891.20 across all CMS Open Payments tracks (General + Research + Ownership) to 14,689 physicians and teaching hospitals in Program Year 2024 - ranking #244 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $5,970,405.97, averaging $407.92 per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer envista-holdings-corporation Envista Holdings Corporation
$6.0M · #244/1,925 · 0.0% industry · PY2024
- TOT $6.0M
- RANK #244
- SHARE 0.0%
- TXN 14,709
- RCP 14,689
- CAT 10
- GEN $6.0M
- TOP1 5.6%
- PY 2024
Volume peers
Nearest volume peer: Coloplast Corp ($6.0M)
Envista Holdings Corporation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
What the Data Shows for Envista Holdings Corporation
Rank #244 of 1,925 companies in CMS Open Payments for 2024 belongs to Envista Holdings Corporation, which reported $5,991,891.20 across 14,709 transactions to 14,689 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $407.36 per transaction and $407.92 per recipient.
The 10-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Compensation for Faculty or Speaker (Medical Education)" at $2.6M, accounting for 44.0% of this company's General Payments and 413 transactions.
General Payment Breakdown by Type
Envista Holdings Corporation made 10 types of general payments. "Compensation for Faculty or Speaker (Medical Education)" is the largest category at $2.6M, 44.0% of General Payments.
Envista Holdings Corporation reports 10 general-payment categories - the top three are Compensation for Faculty or Speaker (Medical Education) (44.0%), Travel and Lodging (24.5%), and Consulting Fee (15.1%). The remaining 7 categories make up 16.3% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
Category breadth matters here: Envista Holdings Corporation files across 10 named CMS general-payment types in Program Year 2024, versus manufacturers that report a single dominant category. The chart and table below enumerate every type with an amount above zero for this company.
How Envista Holdings Corporation divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Faculty or Speaker (Medical Education) | $2.6M | 413 | 44.0% |
| Travel and Lodging | $1.5M | 352 | 24.5% |
| Consulting Fee | $904.5K | 189 | 15.1% |
| Food and Beverage | $535.9K | 12,909 | 9.0% |
| Royalty or License | $334.7K | 15 | 5.6% |
| Compensation for Services Other Than Consulting | $73.0K | 18 | 1.2% |
| Education | $26.0K | 721 | 0.4% |
| Charitable Contribution | $3.8K | 29 | 0.1% |
| Grant | $748.42 | 36 | 0.0% |
| Gift | $354.14 | 7 | 0.0% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $1,368,679.94 (22.9%) of $5,970,405.97 in this company's General Payments records across 8,509 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Envista Holdings Corporation
The five named recipients with the highest reported General Payments from this company
- 1
L Stehen Buchanan
$334,697.85 across 15 reported transactions
- 2
Johnathan White
$332,612.13 across 47 reported transactions
- 3
Xavier Saab
$265,951.73 across 41 reported transactions
- 4
Michael Bicknell
$224,619.18 across 59 reported transactions
- 5
Mehrdad Mehranfar
$210,799.05 across 37 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Envista Holdings Corporation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Envista Holdings Corporation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Envista Holdings Corporation.
Showing 6 of 1,924 companies with CMS-reported payment data.
Ventana Medical Systems, Inc.
$5.9M 69 recipients
Compare payment profiles
Teleflex LLC
$6.0M 17,647 recipients
Compare payment profiles
Cook Incorporated
$6.0M 985 recipients
Compare payment profiles
Zimvie Inc.
$5.9M 45,653 recipients
Compare payment profiles
Renalytix AI, Inc.
$5.9M 1,559 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.